References
- Isaacson PG, Piris MA, Berger F, et al. Splenic B-cell marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. World Health organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 185–187.
- Matutes E, Oscier D, Montalban C, et al. Splenic marginal-zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22:487–395.
- Bennett M, Sharma K, Yegena S, et al. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90:856–858.
- Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107:125–135.
- Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25:127–131.
- Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Rituximab monotherapy is the treatment of choice for splenic marginal zone lymphoma (SMZL). Ann Oncol. 2008;19:Abstract #367.
- Else M, Marin-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159:322–328.
- Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of Splenic Marginal Zone Lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist. 2013;18:190–197.
- Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Validation of the simplified prognostic score for SMZL of the SLSG in a series of patients treated homogeneously with rituximab monotherapy and long term outcome of rituximab responders. 2015Haematologica. 2015;100(s1):269(abstract #P681).
- Fabbri A, Gozzetti A, Lazzi S, et al. Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia. Clin Lymphoma Myeloma. 2006;6:496–499.
- Paydas S, Yavuz S, Disel U, et al. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk Lymphoma. 2003;44:2165–2166.
- Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia. 2008;22:1446–1449.
- Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol. 2003;4:95–103.
- Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996;93:731–736.
- Treon S, Anderson K. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000;27:79–85.
- Andersen MH. Immune regulation by self-recognition: novel possibilities for anticancer immunotherapy. J Natl Cancer Inst. 2015;107::djv154. doi:10.1093/jnci/djv154.
- Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006;46:741–753.